Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
PLoS One ; 16(11): e0259142, 2021.
Article in English | MEDLINE | ID: covidwho-1703055

ABSTRACT

PURPOSE: The aim of this cohort study was to evaluate the development and progression of presbyopia and the status of dry eye-related symptoms from 2017 to 2020, to assess the impact of the COVID-19 pandemic. METHODS: Near add power at 30 cm was measured in 339 participants aged between 40 and 55 from 2017 to 2021 at Japanese eye clinics. Regression analysis of near add power and age was analyzed to compare 2017 with later years up to the pandemic. The prevalence of dry eye-related signs and six common symptoms were compared. RESULTS: The number and mean age (y) of participants were 183 (48.6±4.1) in 2017, 46 (51.3±7.5) in 2019, and 110 (49.2±3.7) in 2020-21, respectively. The mean progression rate of near add power (D/y) was 0.13 for 2017, 0.09 for 2019 (P = 0.028, vs 2017), and 0.08 for 2020-21 (P<0.001, vs 2017). The slope (rate of presbyopia progression) became flatter from 2017 to 2021 and the estimated near add power at the age of 40 increased from 2017 to 2020-2021, implicating presbyopia developed earlier and worsened during the study period. The 2017 values were comparable with previous studies described in 1922 and 2019. The standardized correlation coefficient between age and near add power was 0.816 for 2017, 0.671 for 2019 (P = 0.084, vs 2017), and 0.572 for 2020-21 (P<0.001, vs 2017). Multiple regression analysis revealed age and COVID-19 pandemic were significantly correlated with near add power. The prevalence of dryness irritation, and pain was greater in 2020-21 than in 2017 with no difference in the prevalence of eye fatigue, blurring, and photophobia. There was no difference in the prevalence of short tear break-up time and positive corneal staining among 2017, 2019 and 2020-21. CONCLUSION: Estimated presbyopia developed earlier and progressed slower from 2017 to 2021, the COVID-19 pandemic. Stress and rapid digitalization related to strict infection control and quarantine might be contributing factors.


Subject(s)
COVID-19/epidemiology , Dry Eye Syndromes/epidemiology , Pandemics , Presbyopia/epidemiology , Adult , COVID-19/complications , COVID-19/virology , Cohort Studies , Dry Eye Syndromes/complications , Dry Eye Syndromes/virology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Presbyopia/complications , Presbyopia/virology , Refraction, Ocular/physiology , SARS-CoV-2/pathogenicity , Visual Acuity/physiology
2.
Eye Contact Lens ; 47(4): 168-173, 2021 Apr 01.
Article in English | MEDLINE | ID: covidwho-1140027

ABSTRACT

PURPOSE: To assess the effect of severe acute respiratory syndrome coronavirus-2 infection on the conjunctiva and tear film. METHODS: Thirty-eight patients with confirmed COVID-19 and 31 healthy controls were included in this prospective and observational study. Individuals with COVID-19 formed the patient group, and healthy individuals formed the control group. Conjunctival impression cytology (CIC), TBUT, Schirmer II test, and ocular surface disease index were evaluated in all participants. RESULTS: No significant difference was observed regarding the mean age and gender between the groups (P=0.786 and P=0.122, respectively). The mean TBUT and Schirmer II test results did not differ between the two groups (P=0.496 and P=0.447, respectively). The CIC results revealed decreased density and cell size of goblet cells and moderate to high enlargement, squamous changes, and increased nucleocytoplasmic ratio in nongoblet epithelial cells in the COVID-19 group compared with the control group. Based on the Nelson classification in CIC samples, 60.6% of the COVID-19 group and 19.4% of the control group had changes consistent with grade 2 or above. The presence of neutrophils in CIC was significantly higher in the COVID-19 group (P<0.001), whereas the presence of lymphocyte was similar between the two groups (P=0.247). CONCLUSION: This study revealed the pathological conjunctival alterations in patients with COVID-19 and demonstrated that pathological ocular surface alterations may present even at the beginning of COVID-19 without clinically significant ocular manifestation.


Subject(s)
COVID-19/diagnosis , Conjunctiva/pathology , Conjunctivitis, Viral/diagnosis , Dry Eye Syndromes/diagnosis , Eye Infections, Viral/diagnosis , SARS-CoV-2/isolation & purification , Tears/virology , Adult , COVID-19 Nucleic Acid Testing , Cell Count , Cell Size , Conjunctivitis, Viral/virology , Cross-Sectional Studies , Cytological Techniques , Dry Eye Syndromes/virology , Eye Infections, Viral/virology , Female , Goblet Cells/pathology , Humans , Lymphocytes/pathology , Male , Middle Aged , Neutrophils/pathology , Prospective Studies , SARS-CoV-2/genetics , Young Adult
3.
J Korean Med Sci ; 35(35): e322, 2020 Sep 07.
Article in English | MEDLINE | ID: covidwho-745663

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) has reportedly affected almost 23 million people, with more than 800 thousand deaths globally. There have been a few reports on the ocular manifestations of COVID-19 patients in China but no reports in Korea. The present study aimed to examine ocular manifestations of COVID-19 patients in Korea. METHODS: COVID-19 patients admitted from March 2020 to April 2020 at Keimyung University Dongsan Hospital and Keimyung University Daegu Dongsan Hospital were reviewed retrospectively for ocular manifestations. During the period of hospitalization, ocular symptoms as well as blood test results were noted and analyzed. Patients were then divided into the first-episode and relapsed group and ocular symptoms were analyzed in the groups. RESULTS: A total of 103 patients were included in this study. Among them, 71patients were in the first-episode group and 32 patients in the relapsed group. No significant differences were determined in terms of positivity of ocular symptoms between the first-episode group (12 patients, 16.9%) and the relapsed group (10 patients, 31.3%, P > 0.05). Symptoms of positive upper respiratory infection and lower creatine phosphokinase were determined to be related to positive ocular symptoms. Conjunctival congestion was noted in seven patients. In the subgroup analysis, the conjunctival congestion-positive patients exhibited higher positivity of upper respiratory infection symptoms (100%) as compared with those in the negative group (40%, P = 0.017). CONCLUSION: Positive upper respiratory infection symptoms and lower creatine phosphokinase were determined to be related to ocular symptoms in COVID-19 patients. Among these patients, positive upper respiratory infection symptoms were associated with conjunctival congestion.


Subject(s)
Conjunctival Diseases/pathology , Coronavirus Infections/pathology , Creatine Kinase/blood , Pneumonia, Viral/pathology , Vision Disorders/pathology , Adult , Betacoronavirus/pathogenicity , C-Reactive Protein/analysis , COVID-19 , Conjunctival Diseases/virology , Dry Eye Syndromes/pathology , Dry Eye Syndromes/virology , Female , Humans , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Pandemics , Procalcitonin/blood , Republic of Korea , Retrospective Studies , SARS-CoV-2 , Vision Disorders/virology
SELECTION OF CITATIONS
SEARCH DETAIL